These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods]. Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408 [TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET in malignant lymphoma: significance of positive findings. Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956 [TBL] [Abstract][Full Text] [Related]
5. Nodal staging of lymphoma with whole-body PET: comparison of. Sutinen E; Jyrkkiö S; Varpula M; Lindholm P; Grönroos T; Lehikoinen P; Teräs M; Minn H J Nucl Med; 2000 Dec; 41(12):1980-8. PubMed ID: 11138682 [TBL] [Abstract][Full Text] [Related]
6. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison]. Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362 [TBL] [Abstract][Full Text] [Related]
7. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707 [TBL] [Abstract][Full Text] [Related]
8. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma. Tatsumi M; Kitayama H; Sugahara H; Tokita N; Nakamura H; Kanakura Y; Nishimura T J Nucl Med; 2001 Apr; 42(4):601-8. PubMed ID: 11337549 [TBL] [Abstract][Full Text] [Related]
9. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Kotzerke J; Guhlmann A; Moog F; Frickhofen N; Reske SN Eur J Nucl Med; 1999 Jan; 26(1):31-8. PubMed ID: 9933659 [TBL] [Abstract][Full Text] [Related]
10. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma. Ömür Ö; Baran Y; Oral A; Ceylan Y Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817 [TBL] [Abstract][Full Text] [Related]
11. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma. Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087 [TBL] [Abstract][Full Text] [Related]
12. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease. Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534 [TBL] [Abstract][Full Text] [Related]
13. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335 [TBL] [Abstract][Full Text] [Related]
14. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Shen YY; Kao A; Yen RF Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600 [TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Jerusalem G; Beguin Y; Najjar F; Hustinx R; Fassotte MF; Rigo P; Fillet G Ann Oncol; 2001 Jun; 12(6):825-30. PubMed ID: 11484959 [TBL] [Abstract][Full Text] [Related]
16. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma. Shinya T; Fujii S; Asakura S; Taniguchi T; Yoshio K; Alafate A; Sato S; Yoshino T; Kanazawa S Ann Nucl Med; 2012 Oct; 26(8):616-21. PubMed ID: 22692457 [TBL] [Abstract][Full Text] [Related]
17. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma. Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935 [TBL] [Abstract][Full Text] [Related]
19. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093 [TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography for detection and staging of malignant lymphoma. Buchmann I; Moog F; Schirrmeister H; Reske SN Recent Results Cancer Res; 2000; 156():78-89. PubMed ID: 10802866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]